Alitretinoin: a comprehensive review

Bibliography

• Germain P, Chambon P, Eichele G, et al. International Union of Pharmacology. LX. Retinoic acid receptors. Pharmacol Rev 2006;58:712-25
   PubMed Web of Science ®Google Scholar
• Germain P, Chambon P, Eichele G, et al. International Union of Pharmacology. LXIII. Retinoid X receptors. Pharmacol Rev 2006;58:760-72
   PubMed Web of Science ®Google Scholar
• Wolf G. Is 9-cis-retinoic acid the endogenous ligand for the retinoic acid-X receptor? Nutr Rev 2006;64:532-8
   PubMed Web of Science ®Google Scholar
• Sakuta T, Kanayama T. Marked improvement induced in photoaged skin of hairless mouse by ER36009, a novel RARgamma-specific retinoid, but not by ER35794, an RXR-selective agonist. Int J Dermatol 2006;45:1288-95
   PubMed Web of Science ®Google Scholar
• Gillespie RF, Gudas LJ. Retinoid regulated association of transcriptional co-regulators and the polycomb group protein SUZ12 with the retinoic acid response elements of Hoxa1, RARbeta(2), and Cyp26A1 in F9 embryonal carcinoma cells. J Mol Biol 2007;372:298-316
   PubMed Web of Science ®Google Scholar
• Li M, Indra AK, Warot X, et al. Skin abnormalities generated by temporally controlled RXRalpha mutations in mouse epidermis. Nature 2000;407:633-6
   PubMed Web of Science ®Google Scholar
• Jensen T, Sorensen S, Solvsten H, et al. The vitamin D3 receptor and retinoid X receptors in psoriatic skin: the receptor levels correlate with the receptor binding to DNA. Br J Dermatol 1998;138:225-8
   PubMed Web of Science ®Google Scholar
• DiPiro JT, Talbert RL, Yee GC, et al. Pharmacotherapy: A Pathophysiologic Approach, 6th edition. New York: McGraw-Hill; 2005
   Google Scholar
• Brunton LL, Lazo JS, Parker KL. Goodman & Gilman's The Pharmacological Basis of Therapeutics, 11th edition. New York: McGraw-Hill; 2006
   Google Scholar
• Cheer SM, Foster RH. Alitretinoin. Am J Clin Dermatol 2000;1:307-14
   PubMedGoogle Scholar
• Bollag W, Ott F. Successful treatment of chronic hand eczema with oral 9-cis-retinoic acid. Dermatology 1999;199:308-12
   PubMed Web of Science ®Google Scholar
• Ritchie HE, Brown-Woodman PD, Korabelnikoff A. Effect of co-administration of retinoids on rat embryo development in vitro. Birth Defects Res A Clin Mol Teratol 2003;67:444-51
   PubMed Web of Science ®Google Scholar
• Xu J, Drew PD. 9-Cis-retinoic acid suppresses inflammatory responses of microglia and astrocytes. J Neuroimmunol 2006;171:135-44
   PubMed Web of Science ®Google Scholar
• Dermatitis. In: Marcovitch H, editor. Black's Medical Dictionary. Lanham, MD: The Scarecrow Press, Inc.; 2006
   Google Scholar
• Ruzicka T, Larsen FG, Galewicz D, et al. Oral alitretinoin (9-cis-retinoic acid) therapy for chronic hand dermatitis in patients refractory to standard therapy: results of a randomized, double-blind, placebo-controlled, multicenter trial. Arch Dermatol 2004;140:1453-9
   PubMed Web of Science ®Google Scholar
• Rongioletti F, Zaccaria E, Viglizzo G. Failure of topical 0.1% alitretinoin gel for classic Kaposi sarcoma: first European experience. Br J Dermatol 2006;155:856-7
   PubMed Web of Science ®Google Scholar
• Bodsworth NJ, Bloch M, Bower M, et al. Phase III vehicle-controlled, multi-centered study of topical alitretinoin gel 0.1% in cutaneous AIDS-related Kaposi's sarcoma. Am J Clin Dermatol 2001;2:77-87
   PubMedGoogle Scholar
• Walmsley S, Northfelt DW, Melosky B, et al. Treatment of AIDS-related cutaneous Kaposi's sarcoma with topical alitretinoin (9-cis-retinoic acid) gel. Panretin Gel North American Study Group. J Acquir Immune Defic Syndr 1999;22:235-46
   PubMed Web of Science ®Google Scholar
• Bodsworth N. Topical 9-cis-retinoic acid (Panretin) gel as treatment of cutaneous AIDS-related Kaposi's sarcoma: interim results of an international, placebo-controlled trial (ALRT 1057-503) [Abstract 618/22277]. International Panretin KS Study Group. Int Conf AIDS 1998;12:317
   Google Scholar
• Ligand Pharmaceuticals. Panretin® (alitretinoin) prescribing information; 2006
   Google Scholar
• Aboulafia DM, Norris D, Henry D, et al. 9-cis-retinoic acid capsules in the treatment of AIDS-related Kaposi sarcoma: results of a phase 2 multicenter clinical trial. Arch Dermatol 2003;139:178-86
   PubMed Web of Science ®Google Scholar
• Miles SA, Dezube BJ, Lee JY, et al. Antitumor activity of oral 9-cis-retinoic acid in HIV-associated Kaposi's sarcoma. AIDS 2002;16:421-9
   PubMed Web of Science ®Google Scholar
• Baumann L, Vujevich J, Halem M, et al. Open-label pilot study of alitretinoin gel 0.1% in the treatment of photoaging. Cutis 2005;76:69-73
   PubMed Web of Science ®Google Scholar
• Maloney DM, Schmidt JD, Duvic M. Alitretinoin gel to treat pyogenic granuloma. J Am Acad Dermatol 2002;47:969-70
   PubMed Web of Science ®Google Scholar
• Bassiri-Tehrani S, Ba BA, Cohen DE. Treatment of cutaneous T-cell lymphoma with alitretinoin gel. Int J Dermatol 2002;41:104-6
   PubMed Web of Science ®Google Scholar
• Duvic M, Friedman-Kien AE, Galpin J, et al. Phase I/II clinical trial supports safety and efficacy of ALRT 1057 topical retinoid gel for Kaposi's sarcoma [Abstract]. International Conference on AIDS 1996;11:27
   Google Scholar
• Miller VA, Rigas JR, Benedetti FM, et al. Initial clinical trial of the retinoid receptor pan agonist 9-cis retinoic acid. Clin Cancer Res 1996;2:471-5
   PubMed Web of Science ®Google Scholar